![]() |
Event-free and overall survival results from NeoALTTO trial
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial were presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
More... |
| All times are GMT -7. The time now is 09:46 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021